STOCK TITAN

Ardelyx (ARDX) Financials

ARDX NASDAQ
Trailing 12 months to September 30, 2026
Revenue $468.2M +17.6% YoY
Net Income -$55.5M n/m YoY
EPS (Diluted) -$0.23 n/m YoY
Free Cash Flow -$16.0M n/m YoY
Market Cap $751.6M as of Nov 20, 2026
Price / Sales 1.6x on $468.2M revenue, trailing 12 months to September 30, 2026
Price / Earnings n/m net loss, so no earnings multiple, trailing 12 months to September 30, 2026
Price / Book 4.6x on $164.0M equity, Q3 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 20, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q3 FY2026, ended Sep 30, 2026 Reported Currency USD FYE December

Newest figures come from the 10-Q for Q3 FY2026, filed Nov 3, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the ARDX SEC filings page.

Ardelyx, Inc. (ARDX) reported $468.2M in revenue over the twelve months to Sep 30, 2026, up 17.6% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 14 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI ARDX FY2025

Ardelyx's revenue has reached commercial scale, but rising overhead and leverage still prevent strong gross economics from becoming operating profit.

From FY2024 to FY2025, revenue grew 22.1% and gross profit grew 29.9%. Yet operating margin fell 1.7 percentage points, showing that incremental gross profit was absorbed by overhead instead of reaching operating profit.

FY2025 operating cash flow was -$42.5M, close to free cash flow of -$44.0M; the narrow gap indicates cash use tracks ongoing operations more closely than a capital-intensive model would. Capital expenditures were only $1.5M, so the cash shortfall was chiefly operational rather than an expansion-heavy investment burden.

The capital structure became more debt-supported: debt-to-equity reached 1.2x in FY2025, up from 0.9x in FY2024. Liabilities rose to 66.7% of assets from 60.2%, meaning balance-sheet leverage increased alongside the company's revenue expansion.

[ NOT FINANCIAL ADVICE ]

Financial Health Signals

Profitability Growth Leverage Liquidity CashFlow Returns 43 / 100
Financial Health Score 43/100

Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Ardelyx, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability
15

Profitability ranks operating companies on their operating margin with gains on asset sales taken out, averaged over the last three fiscal years with the newest counting most, and in smaller part on how steady that margin has been. Ardelyx, Inc. scores 15/100 on it among other operating companies.

Growth
97

Growth ranks operating companies on the yearly rate at which revenue compounded across the last three fiscal years (the last two where the earliest reports no revenue), counted in the currency each company reports in so that a move in the exchange rate is not read as growth. Ardelyx, Inc. scores 97/100 on it among other operating companies.

Leverage
29

Ardelyx, Inc. carried $1.21 of long-term debt for every $1 of shareholders' equity at the end of fiscal year 2025, a debt-to-equity ratio of 1.21. With no positive EBITDA in fiscal year 2025, Ardelyx, Inc. is ranked on that ratio rather than on net debt against EBITDA, a lower ratio being the safer one, and scores 29/100 among other operating companies measured the same way.

Liquidity
89

Ardelyx, Inc. held $4.31 of current assets for every $1 of current liabilities at the end of fiscal year 2025, a current ratio of 4.31. Liquidity ranks operating companies on that ratio, and Ardelyx, Inc. scores 89/100 among other operating companies.

Cash Flow
9

Cash Flow ranks operating companies on their free cash flow margin, which is operating cash flow less capital spending as a share of revenue, averaged over the last three fiscal years with the newest weighted most. Ardelyx, Inc. scores 9/100 on it among other operating companies.

Returns
20

Returns ranks operating companies on their return on capital employed, which is operating income against total assets less current liabilities, averaged over three fiscal years with the newest weighted most, and in smaller part on how steady that return has been. Ardelyx, Inc. scores 20/100 on it among other operating companies.

Altman Z-Score Distress
-0.05

Ardelyx, Inc. scores -0.05, below the 1.81 distress threshold. The score is pulled down most by an accumulated deficit of $946.9M against total assets of $501.6M. This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Weak
3/9

Ardelyx, Inc. passes 3 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.

Earnings Quality No Cash Backing
N/A

Ardelyx, Inc. reported a net loss of $61.6M while operations used $42.5M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk
N/A

Ardelyx, Inc. reported an operating loss of $41.0M against $20.1M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue
$127.7M
YoY+15.7%
QoQ+5.6%
5Y CAGR+155.5%

Ardelyx, Inc. generated $127.7M in revenue in Q3 2026. This represents an increase of 15.7% from the same quarter a year earlier. Against the prior quarter it is up 5.6%.

EBITDA
$4.6M
YoY-16.7%
QoQn/m

Ardelyx, Inc.'s EBITDA was $4.6M in Q3 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 16.7% from the same quarter a year earlier. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Net Income
-$737K
YoYn/m
QoQn/m
5Y CAGRn/m
10Y CAGRn/m

Ardelyx, Inc. reported a net loss of $737K in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

EPS (Diluted)
$0.00
YoYn/m
QoQn/m

Ardelyx, Inc. earned $0.00 per diluted share (EPS) in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Cash & Balance Sheet

Free Cash Flow
$2.2M
YoY+938.8%
QoQn/m

Ardelyx, Inc. generated $2.2M in free cash flow in Q3 2026, representing cash available after capex. This represents an increase of 938.8% from the same quarter a year earlier. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Cash & Debt
$46.3M
YoY+8.4%
QoQ-52.3%
5Y CAGR-9.3%
10Y CAGR-11.7%

Ardelyx, Inc. held $46.3M in cash against $252.4M in long-term debt as of Q3 2026.

Shares Outstanding
251M
YoY+3.5%
QoQ+0.9%

Ardelyx, Inc. had 251M shares outstanding in Q3 2026. This represents an increase of 3.5% from the same quarter a year earlier. Against the prior quarter it is up 0.9%.

Dividends Per Share

Not reported for Q3 2026.

Margins & Returns

Gross Margin
96.4%
YoY+0.1pp
QoQ+1.2pp
5Y change-3.6pp

Ardelyx, Inc.'s gross margin was 96.4% in Q3 2026, indicating the percentage of revenue retained after direct costs. This is up 0.1 percentage points from the same quarter a year earlier. Against the prior quarter it is up 1.2 percentage points.

Operating Margin
3.1%
YoY-1.1pp
QoQ+13.4pp

Ardelyx, Inc.'s operating margin was 3.1% in Q3 2026, reflecting core business profitability. This is down 1.1 percentage points from the same quarter a year earlier. Against the prior quarter it is up 13.4 percentage points.

Net Margin
-0.6%
YoY+0.3pp
QoQ+13.3pp

Ardelyx, Inc.'s net profit margin was -0.6% in Q3 2026, showing the share of revenue converted to profit. This is up 0.3 percentage points from the same quarter a year earlier. Against the prior quarter it is up 13.3 percentage points.

Return on Equity
-0.4%
YoY+0.2pp
QoQ+10.8pp
5Y change+53.1pp
10Y change+12.6pp

Ardelyx, Inc.'s quarterly ROE was -0.4% in Q3 2026: one quarter's net income over shareholder equity, not annualized. This is up 0.2 percentage points from the same quarter a year earlier. Against the prior quarter it is up 10.8 percentage points.

Capital Allocation

R&D Spending
$25.2M
YoY+39.5%
QoQ-3.5%
5Y CAGR+1.2%

Ardelyx, Inc. invested $25.2M in research and development in Q3 2026. This represents an increase of 39.5% from the same quarter a year earlier. Against the prior quarter it is down 3.5%.

Capital Expenditures
$0
YoY-100.0%
QoQ-100.0%

Ardelyx, Inc. reported no capital expenditure in Q3 2026. This represents a decrease of 100.0% from the same quarter a year earlier. Against the prior quarter it is down 100.0%.

Share Buybacks

Not reported for Q3 2026.

ARDX Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

ARDX quarterly income statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Revenue$127.7M+15.7%$120.9M+23.8%$94.5M+27.5%$125.2M+7.8%$110.3M+12.3%$97.7M+33.4%$74.1M+61.0%$116.1M+237.9%
Cost of Revenue$4.5M+14.0%$5.8M-53.6%$4.8M-60.9%$10.8M-40.6%$4.0M-74.7%$12.4M+31.4%$12.3M+72.6%$18.3M+259.7%
Gross Profit$123.1M+15.8%$115.1M+35.0%$89.7M+45.1%$114.4M+16.9%$106.3M+28.9%$85.3M+33.7%$61.8M+58.9%$97.9M+234.2%
R&D Expenses$25.2M+39.5%$26.1M+66.6%$20.2M+35.1%$22.9M+67.2%$18.1M+18.0%$15.7M+22.8%$14.9M+41.2%$13.7M+43.5%
SG&A Expenses$93.9M+12.3%$101.4M+20.8%$102.3M+22.9%$86.4M+13.6%$83.6M+28.7%$84.0M+29.9%$83.2M+57.0%$76.1M+59.3%
Operating Income$4.0M-13.8%-$12.4Mn/m-$32.8Mn/m$5.1M-37.2%$4.7M+109.0%-$14.4Mn/m-$36.3Mn/m$8.1Mn/m
EBITDA$4.6M-16.7%-$11.8Mn/m-$31.9Mn/m$6.0M-30.3%$5.6M+100.7%-$13.8Mn/m-$35.7Mn/m$8.6Mn/m
Interest Expense$5.9M+1.4%$5.0M+13.8%$5.6M+33.6%$5.8M+45.2%$5.8M+72.7%$4.4M+31.0%$4.2M+77.9%$4.0M+128.0%
Income Tax$90K-11.8%$110K+10900.0%$8K-99.1%$7K-80.0%$102K+137.2%$1K-98.5%$859K+609.9%$35K-89.5%
Net Income-$737Kn/m-$16.7Mn/m-$37.6Mn/m-$407K-108.8%-$969Kn/m-$19.1Mn/m-$41.1Mn/m$4.6Mn/m
EPS (Basic)$0.00n/m-$0.07n/m-$0.15n/m-$0.01$0.00n/m-$0.08n/m-$0.17n/m$0.02n/m
EPS (Diluted)$0.00n/m-$0.07n/m-$0.15n/m-$0.01$0.00n/m-$0.08n/m-$0.17n/m$0.02n/m
Diluted Shares (Avg)250M+3.3%248M+3.4%246M+3.0%N/A242M+2.5%240M+2.3%239M+2.4%N/A

ARDX Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

ARDX quarterly balance sheet
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Total Assets$587.5M+20.8%$575.9M+23.4%$504.5M+23.0%$501.6M+15.1%$486.2M+32.2%$466.8M+35.9%$410.2M+19.8%$435.8M+46.4%
Current Assets$441.4M+19.9%$441.9M+25.7%$381.9M+22.1%$382.3M+7.3%$368.0M+29.5%$351.6M+33.7%$312.7M+21.2%$356.5M+44.8%
Cash & Equivalents$46.3M+8.4%$97.2M+7.9%$31.2M+1.3%$68.0M+4.7%$42.7M-9.9%$90.0M+115.0%$30.8M-14.8%$64.9M+202.4%
Short-Term Investments$239.0M+19.5%$184.6M+24.4%$206.9M+13.0%$196.7M+6.2%$200.0M+39.9%$148.4M+3.0%$183.1M+10.0%$185.2M+13.7%
Inventory$157.6M+21.8%$139.0M+12.8%$128.0M+20.9%$123.1M+35.0%$129.4M+51.9%$123.3M+47.7%$105.9M+34.3%$91.2M+84.3%
Accounts Receivable$93.4M+22.0%$100.4M+60.4%$82.8M+78.3%$71.8M+24.5%$76.6M+44.0%$62.6M+68.0%$46.5M+65.0%$57.7M+161.9%
Long-Term Investments$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m
Total Liabilities$423.5M+27.6%$426.9M+30.4%$355.9M+34.5%$334.7M+27.5%$331.9M+58.4%$327.2M+66.5%$264.5M+38.1%$262.5M+100.7%
Current Liabilities$127.8M+53.3%$132.2M+61.8%$109.6M+44.5%$88.6M+13.8%$83.4M+18.3%$81.7M+30.9%$75.8M+33.3%$77.8M+54.4%
Non-Current Liabilities$295.7M+19.0%$294.7M+20.0%$246.3M+30.5%$246.1M+33.3%$248.5M+78.7%$245.5M+83.1%$188.7M+40.2%$184.6M+129.7%
Long-Term Debt$252.4M+24.8%$251.8M+25.0%$203.5M+34.5%$202.8M+34.5%$202.1M+100.7%$201.4M+100.9%$151.3M+51.6%$150.9M+202.8%
Total Equity$164.0M+6.3%$149.0M+6.8%$148.6M+2.0%$166.9M-3.7%$154.3M-2.5%$139.5M-5.1%$145.7M-3.5%$173.3M+3.9%
Retained Earnings-$1.0Bn/m-$1.0Bn/m-$984.5Mn/m-$946.9Mn/m-$946.5Mn/m-$945.6Mn/m-$926.5Mn/m-$885.3Mn/m

Not reported in any period shown, so not listed: Goodwill.

ARDX Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

ARDX quarterly cash flow statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Operating Cash Flow$2.2M+494.8%-$6.4Mn/m-$32.2Mn/m$21.0M+113.6%$365K-27.1%-$25.3Mn/m-$38.5Mn/m$9.8Mn/m
Depreciation & Amortization$621K-31.4%$604K-4.3%$915K+52.0%$921K+78.8%$905K+66.4%$631K+10.9%$602K+38.4%$515K+42.3%
Stock-Based Compensation$15.1M+18.5%$15.3M+31.1%$14.2M+17.1%N/A$12.7M+39.5%$11.7M+8.5%$12.1M+58.7%N/A
Capital Expenditures$0-100.0%$13K-98.0%$69K-78.8%$361K-39.1%$156K+13.9%$650K+396.2%$325K+116.7%$593K+1279.1%
Free Cash Flow$2.2M+938.8%-$6.4Mn/m-$32.3Mn/m$20.6M+123.4%$209K-42.6%-$26.0Mn/m-$38.8Mn/m$9.2Mn/m
Investing Cash Flow-$54.0Mn/m$22.7M-35.1%-$10.0M-450.6%$3.8Mn/m-$50.5M-2257.6%$34.9M+48.4%$2.9Mn/m-$41.6Mn/m
Financing Cash Flow$959K-65.9%$49.7M+0.1%$5.4M+267.2%$557K-98.9%$2.8M+4.3%$49.7M+2988.1%$1.5M-97.2%$49.3M+89.8%

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

ARDX Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

ARDX quarterly financial ratios
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Gross Margin96.4%+0.1pp95.2%+7.9pp94.9%+11.5pp91.3%+7.1pp96.4%+12.4pp87.3%+0.2pp83.4%-1.1pp84.3%-1.0pp
Operating Margin3.1%-1.1pp-10.3%+4.5pp-34.7%+14.3pp4.1%-2.9pp4.2%+2.0pp-14.7%+3.9pp-49.0%+4.6pp7.0%+88.4pp
Net Margin-0.6%+0.3pp-13.8%+5.7pp-39.8%+15.7pp-0.3%-4.3pp-0.9%-0.1pp-19.5%+2.9pp-55.5%+2.1pp4.0%+87.8pp
Return on Equity-0.4%+0.2pp-11.2%+2.4pp-25.3%+2.9pp-0.2%-2.9pp-0.6%-0.1pp-13.7%-2.5pp-28.2%-10.7pp2.7%+19.9pp
Return on Assets-0.1%+0.1pp-2.9%+1.2pp-7.4%+2.6pp-0.1%-1.1pp-0.2%0.0pp-4.1%+0.7pp-10.0%-2.3pp1.1%+10.8pp
Current Ratio3.45-1.0x3.34-1.0x3.49-0.6x4.31-0.3x4.41+0.4x4.30+0.1x4.12-0.4x4.58-0.3x
Debt-to-Equity1.54+0.2x1.69+0.2x1.37+0.3x1.21+0.3x1.31+0.7x1.44+0.8x1.04+0.4x0.87+0.6x
Liabilities-to-Equity2.58+0.4x2.86+0.5x2.39+0.6x2.00+0.5x2.15+0.8x2.35+1.0x1.82+0.5x1.51+0.7x
Asset Turnover0.220.0x0.210.0x0.190.0x0.250.0x0.230.0x0.210.0x0.180.0x0.27+0.2x
FCF Margin1.7%+1.5pp-5.3%+21.3pp-34.2%+18.1pp16.4%+8.5pp0.2%-0.2pp-26.6%+0.1pp-52.3%+25.6pp7.9%+33.4pp

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.

Company Fiscal year Revenue Net income Net margin Market cap Health score
Ardelyx, Inc. ARDX FY2025 $407.3M -$61.6M -15.1% $751.6M 43/100
Lexicon Pharmaceuticals, Inc. LXRX FY2025 $49.8M -$50.3M N/A $681.2M 66/100
Oric Pharmaceuticals, Inc. ORIC FY2025 N/A -$129.5M N/A $764.9M —
Solid Biosciences Inc. SLDB FY2025 N/A -$174.3M N/A $697.6M —
Aura Biosciences, Inc. AURA FY2025 N/A -$106.2M N/A $715.0M —
Sagimet Biosciences Inc. SGMT FY2025 N/A -$51.0M N/A $648.0M —

Frequently Asked Questions

Ardelyx, Inc. (ARDX) reported $407.3M in total revenue for fiscal year 2025. This represents a 22.1% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

Ardelyx, Inc. (ARDX) revenue grew by 22.1% year-over-year, from $333.6M to $407.3M in fiscal year 2025.

No, Ardelyx, Inc. (ARDX) reported a net loss of $55.5M over the trailing 12 months to September 30, 2026. In fiscal year 2025 it reported a net loss of $61.6M, with a net profit margin of -15.1%.

Ardelyx, Inc. (ARDX) reported diluted earnings per share of -$0.26 for fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Ardelyx, Inc. (ARDX) had EBITDA of -$37.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

As of fiscal year 2025, Ardelyx, Inc. (ARDX) had $68.0M in cash and equivalents against $202.8M in long-term debt.

Ardelyx, Inc. (ARDX) had a gross margin of 90.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

Ardelyx, Inc. (ARDX) had an operating margin of -10.1% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

Ardelyx, Inc. (ARDX) had a net profit margin of -15.1% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

Ardelyx, Inc. (ARDX) has a return on equity of -36.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

Ardelyx, Inc. (ARDX) recorded an outflow of $44.0M in free cash flow during fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

Ardelyx, Inc. (ARDX) recorded an outflow of $42.5M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

Ardelyx, Inc. (ARDX) had $501.6M in total assets as of fiscal year 2025, including both current and long-term assets.

Ardelyx, Inc. (ARDX) invested $1.5M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

Ardelyx, Inc. (ARDX) invested $71.5M in research and development during fiscal year 2025.

Ardelyx, Inc. (ARDX) had 245M shares outstanding as of fiscal year 2025.

Ardelyx, Inc. (ARDX) had a current ratio of 4.31 as of fiscal year 2025, which is generally considered healthy.

Ardelyx, Inc. (ARDX) had a debt-to-equity ratio of 1.21 as of fiscal year 2025. We compute it as long-term debt divided by total shareholder equity, where long-term debt is the noncurrent part of the company's borrowings, so debt due within the next twelve months is not counted.

Ardelyx, Inc. (ARDX) had a liabilities-to-equity ratio of 2.00 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity.

Ardelyx, Inc. (ARDX) had a return on assets of -12.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Ardelyx, Inc. (ARDX) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to September 30, 2026). The market capitalization is $751.6M as of Nov 20, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

Ardelyx, Inc. (ARDX) trades at 1.6x sales, its market capitalization divided by $468.2M revenue, trailing 12 months to September 30, 2026. The market capitalization is $751.6M as of Nov 20, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

At the end of fiscal year 2025, Ardelyx, Inc. (ARDX) held $264.7M in cash, cash equivalents and investments, and reported an operating cash outflow of $42.5M over that year. Dividing the one by the other, the reported balance equals about 75 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

Ardelyx, Inc. (ARDX) has an Altman Z-Score of -0.05, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

Ardelyx, Inc. (ARDX) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Ardelyx, Inc. (ARDX) reported a net loss of $61.6M while operations used $42.5M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Ardelyx, Inc. (ARDX) reported an operating loss of $41.0M against $20.1M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

Ardelyx, Inc. (ARDX) scores 43 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is the average of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.

Back to top